



**Providing Choice & Value**  
Generic CT and MRI Contrast Agents

**FRESENIUS  
KABI**

**CONTACT REP**

**AJNR**

**The Risk of Stroke and TIA in Nonstenotic Carotid Plaques: A Systematic Review and Meta-Analysis**

N. Singh, M. Marko, J.M. Ospel, M. Goyal and M. Almekhlafi

This information is current as of July 24, 2025.

*AJNR Am J Neuroradiol* 2020, 41 (8) 1453-1459

doi: <https://doi.org/10.3174/ajnr.A6613>

<http://www.ajnr.org/content/41/8/1453>

# The Risk of Stroke and TIA in Nonstenotic Carotid Plaques: A Systematic Review and Meta-Analysis

N. Singh, M. Marko, J.M. Ospel, M. Goyal, and M. Almekhlafi



## ABSTRACT

**BACKGROUND:** Severe carotid stenosis carries a high risk of stroke. However, the risk of stroke with nonstenotic carotid plaques (<50%) is increasingly recognized.

**PURPOSE:** We aimed to summarize the risk of TIA or stroke in patients with nonstenotic carotid plaques.

**DATA SOURCES:** We performed a comprehensive systematic review and meta-analysis in patients with acute ischemic stroke in whom carotid imaging was performed using MEDLINE and the Cochrane Database, including studies published up to December 2019.

**STUDY SELECTION:** Included studies had >10 patients with <50% carotid plaques on any imaging technique and reported the incidence or recurrence of ischemic stroke/TIA. High-risk plaque features and the risk of progression to stenosis >50% were extracted if reported.

**DATA SYNTHESIS:** We identified 31 studies reporting on the risk of ipsilateral stroke/TIA in patients with nonstenotic carotid plaques. Twenty-five studies ( $n = 13,428$  participants) reported on first-ever stroke/TIA and 6 studies ( $n = 122$  participants) reported on the recurrence of stroke/TIA.

**DATA ANALYSIS:** The incidence of first-ever ipsilateral stroke/TIA was 0.5/100 person-years. The risk of recurrent stroke/TIA was 2.6/100 person-years and increased to 4.9/100 person-years if intraplaque hemorrhage was present. The risk of progression to severe stenosis (>50%) was 2.9/100 person-years (8 studies,  $n = 448$  participants).

**LIMITATIONS:** Included studies showed heterogeneity in reporting stroke etiology, the extent of stroke work-up, imaging modalities, and classification systems used for characterizing carotid stenosis.

**CONCLUSIONS:** The risk of recurrent stroke/TIA in nonstenotic carotid plaques is not negligible, especially in the presence of high-risk plaque features. Further research is needed to better define the significance of nonstenotic carotid plaques for stroke etiology.

**ABBREVIATIONS:** ASyNC = asymptomatic nonstenotic carotid plaques; ESUS = embolic stroke of undetermined source; PICOS = Population, Intervention; Control or comparator; Outcomes; SyNC = symptomatic nonstenotic carotid plaques; ECST = European Carotid Surgery Trial

The etiology of acute ischemic stroke is crucial to guide further management and for the prevention of recurrent events. Carotid stenosis as the underlying etiology is found in up to 20%

of cerebrovascular ischemic events.<sup>1,2</sup> Current American Heart Association/American Stroke Association guidelines recommend carotid revascularization only in patients with symptomatic carotid stenosis of >50%.<sup>3</sup> This recommendation is supported by data from the European Carotid Surgery Trial (ECST) and North America Symptomatic Carotid Endarterectomy Trial (NASCET), which showed a significant reduction of future strokes after revascularization of symptomatic severe carotid stenoses but modest benefit in moderate stenoses.<sup>4,5</sup> Thus, the management of symptomatic patients with <50% stenosis is undetermined. In addition, the risk of stroke and TIA with carotid plaques of <50% is not well-defined, though recent evidence suggests their potential role in stroke,<sup>6-9</sup> especially in those classified as cryptogenic. Moreover, certain morphologic features of carotid plaques are independent risk factors of stroke/TIA, irrespective of the degree of stenosis.<sup>6,10,11</sup> In a recent meta-analysis, mild carotid


Received March 7, 2020; accepted after revision April 29.

From the Departments of Clinical Neurosciences (N.S., M.M., J.M.O., M.G., M.A.), and Diagnostic Imaging (M.G., M.A.), Foothills Medical Center, University of Calgary, Calgary, Alberta, Canada; Department of Neurology (M.M.), Medical University of Vienna, Vienna, Austria; and Department of Radiology (J.M.O.), University Hospital of Basel, Basel, Switzerland.

N. Singh and M. Marko contributed equally to this publication.

Please address correspondence Nishita Singh, MD, Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, AB, T2N 4M1, University of Calgary, Calgary, AB, Canada; e-mail: nishitanerology@gmail.com; @nishita\_singh3

 Indicates article with supplemental on-line appendix and tables.

 Indicates article with supplemental on-line photos.

<http://dx.doi.org/10.3174/ajnr.A6613>

stenosis with “high-risk plaque features” was significantly more common in patients with an embolic stroke of undetermined source (ESUS) ipsilateral to the side of stroke compared with the contralateral side.<sup>12</sup> Moreover, there are studies proposing carotid revascularization as a treatment option in patients with nonstenotic carotid plaques with recurrent ipsilateral strokes despite adequate medical treatment.<sup>13,14</sup>

We conducted a meta-analysis to estimate the risk of incident ischemic stroke/TIA in asymptomatic nonstenotic carotid plaques (ASyNC) as well as the risk of recurrent stroke/TIA in patients with symptomatic nonstenotic carotid plaques (SyNC).

## MATERIALS AND METHODS

Our strategy to address the primary question above was informed by the Population, Intervention; Control or comparator; Outcomes (PICOS) framework recommended by the Cochrane Collaboration Handbook for Systematic Reviews of Interventions.<sup>15</sup> Details are provided in the On-line Appendix.

Briefly, we included studies of individuals with asymptomatic or symptomatic nonstenotic carotid plaques (<50%) measured with any imaging technique (sonography/CT angiography/MR angiography/DSA). The primary outcome was the future risk of stroke/TIA in the ASyNC group and the risk of recurrent stroke/TIA in those with symptomatic nonstenotic carotid plaques. Retinal ischemic events (such as amaurosis fugax) were infrequently mentioned in the included studies and, if mentioned, were included in the subgroup of TIAs.

### Search Strategy

We performed and reported this review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.<sup>16</sup> We registered our protocol a priori in the PROSPERO international prospective register of systematic reviews (<https://www.crd.york.ac.uk/PROSPERO>; No. 162497). Data were collected from published studies; hence, ethics approval and consent were not required.

Our primary question was to describe the natural history of ASyNC and the risk of recurrent stroke/TIA in patients with symptomatic nonstenotic carotid plaques (SyNC). Natural history incorporates both the risk of ischemic stroke/TIA on follow-up and the risk of progression to severe stenosis in patients with asymptomatic, nonstenotic carotid plaques. We defined nonstenotic carotid plaques as carotid plaques with <50% stenosis. SyNC was defined as a carotid plaque with <50% luminal stenosis and an ipsilateral stroke/TIA. In studies that grouped patients into <30%, 30%–70%, and >70% stenosis, only the group of patients with <30% stenosis was included in the analysis to avoid overestimation of the predefined outcome by including a subgroup of patients with 50%–70% carotid stenosis.

Secondary questions included the effects of plaque features on the risk of stroke/TIA. Plaque features include intraplaque hemorrhage, lipid-rich necrotic core, ulceration, fibrous cap, calcification, and thrombus. Additionally, we aimed to assess whether treatment affects the risk of future or recurrent ischemic stroke/TIA. Treatments included medical (antiplatelets, statins) and interventional (endarterectomy or stent placement) management. Details of the framework, search strategy, study selection with

inclusion and exclusion criteria, and bias assessment, including publication bias, are mentioned in the On-line Appendix (On-line Figs 1–7).

### Statistical Analysis

Analyses were performed using STATA/IC, Version 14.0 (StataCorp). The meta-analyses were performed using a random-effects model of variance. Heterogeneity was calculated using the Higgins  $I^2$  statistic (with associated  $P$  values). We also evaluated the primary outcomes through subgroup analyses using a stratified random-effects meta-analysis. Publication bias was assessed using the Egger test.

## RESULTS

Summary findings of key data-extraction elements are presented in On-line Tables 1 and 2.

### Risk of First-Ever Stroke/TIA in Asymptomatic Nonstenotic Carotid Plaques

Of the total 25 studies involving 24,847 participants (18 prospective, 2 randomized trials, 6 retrospective), the mean age was 67.5 years (range, 58.1–78.7 years), and men represented 50.4%. The classification of stroke etiology using the Trial of Org 10172 in Acute Stroke Treatment criteria was mentioned in only 3 studies.<sup>17–19</sup> Grading of the degree of stenosis was predominantly based on the NASCET criteria<sup>5</sup> and other United States–based classification systems. The average follow-up, reported in 20 studies, was 4.8 years.


Of 24,847 participants, 13,428 (54%) had ASyNC at baseline; the remaining 11,419 (45.9%) were not included in the analysis because they either had no stenosis or were classified into a 30%–70% stenosis group in the study. During a mean follow-up of 4.4 years, 730 subjects (5.4%) with ASyNC developed ischemic stroke/TIA. The incidence rate of stroke/TIA in ASyNC was 0.5/100 person-years (Fig 1).

### Risk of Recurrent Stroke/TIA in Symptomatic Nonstenotic Carotid Plaques

Of a total of 680 participants with SyNC in 14 studies, the mean age was 70.2 years, and most were men ( $n = 454$ , 66.7%). Classification per the Trial of Org 10172 in Acute Stroke Treatment criteria was mentioned in 8 studies.<sup>6,20–26</sup> Most studies ( $n = 9$ ) used the NASCET criteria<sup>5</sup> to define the degree of stenosis.

Six studies<sup>8,13,14,20,27,28</sup> ( $n = 122$ ) reported recurrence of ischemic stroke/TIA ( $n = 20$ , 16.4%) during a mean follow-up of 3.1 years. The incidence rate of recurrent stroke in this population was 2.6/100 person-years (Fig 2).

All except 4 studies<sup>13,14,20,27</sup> reported plaque features that were associated with a higher risk of recurrent stroke/TIA. These were intraplaque hemorrhage,<sup>29</sup> ulceration,<sup>25,29</sup> echolucent plaques,<sup>10</sup> hyperintense plaque,<sup>19</sup> irregular plaque,<sup>30</sup> and fibrous cap with a lipid-rich core.<sup>31</sup> Three studies<sup>13,14,27</sup> found intraplaque hemorrhage associated with a high rate of recurrent ischemic events: 4.9/100 person-years (95% CI, 1.6–8.1 person-years; Fig 3). For the remaining plaque features, the data were insufficient for a meta-analysis.



**FIG 1.** Incidence rate (per 100 person-years) of stroke in patients with ASyNC. ES indicates effect size.

Ten studies reported treatment strategies for patients with SyNC. Of those, 5 used medical treatment (antiplatelets, statins) alone,<sup>6,21,23,26,27</sup> 3 reported a combination of medical treatment and carotid revascularization,<sup>8,20,28</sup> 1 study reported both surgical and endovascular management,<sup>14</sup> and 1 study reported only surgical outcomes.<sup>13</sup> The low numbers in these arms were insufficient to perform a meta-analysis.

#### **Risk of Progression to >50% Stenosis in ASyNC**


Eight studies ( $n = 2223$  participants) assessed stenosis progression from <50% to >50%. Overall, 448 of 2223 (20.2%) patients with ASyNC had stenosis progression. The pooled risk of progression was 11% (95% CI, 10%–12%;  $I^2 = 0$ ,  $P < .01$ ) during a mean follow-up of 6.0 years (Fig 4).

#### **Sensitivity Analyses**


Detailed analyses as per study design and imaging technique for both ASyNC and SyNC are provided in the On-line Appendix (On-line Figs 8–11).

#### **DISCUSSION**

Carotid stenosis with >50% luminal narrowing accounts for 10%–20% of all strokes.<sup>32,33</sup> The long-term risk of ipsilateral stroke in patients with >70% stenosis was 28.3% at 3 years in NASCET<sup>5</sup> and 19% at 5 years in the ECST.<sup>4</sup> These risks were significantly reduced after carotid revascularization. The long-term risk of ipsilateral stroke in carotid stenosis of <50% during 5 years was 18.7% in the NASCET and 8.2% in the ECST.<sup>4,5</sup> Recently, multiple studies have shown an association between nonstenotic (<50%) carotid plaques and ischemic stroke,<sup>7,13,19</sup> suggesting that certain carotid plaques might be an important source of stroke irrespective of the degree of stenosis. Our reported incidence of recurrent ipsilateral stroke/TIA in symptomatic, nonstenotic (<50%) carotid plaques, which substantially increases in the presence of high-risk plaque features, is comparable with the risk of recurrent strokes in stenotic (>50%) carotid plaques per NASCET and the ECST (around 9% and 4% per year, respectively).<sup>4,5</sup> In contrast, the incidence of first-ever TIA or stroke in asymptomatic nonstenotic carotid plaques is lower compared with a 3%–4% annual incidence of stroke with severe



**FIG 2.** Incidence rate (per 100 person-years) of recurrent stroke in patients with SyNC. ES indicates effect size.




**FIG 3.** Incidence rate (per 100 person-years) of recurrent stroke in patients with SyNC, with intraplaque hemorrhage (IPH). ES indicates effect size.

(>70%) carotid stenosis per the Asymptomatic Carotid Atherosclerosis Study in the United States and the Asymptomatic Carotid Surgery Trial in Europe.<sup>34,35</sup>

In this meta-analysis, the relatively high rate of recurrent strokes in SyNC can be explained by the high-risk patients

who already had at least 1 stroke with associated risk factors. In addition, because most studies included strokes of different etiologies, nonstenotic plaques might be an incidental finding in many cases, and these recurrent strokes are due to other unidentified etiologies (eg, cardioembolic). Also, the



**FIG 4.** Risk of progression of <50% stenosis to >50% stenosis in ASyNC. ES indicates effect size.

stroke etiology work-up was not uniform, and none of the studies that reported stroke recurrence outlined the investigations performed to rule out a cardioembolic source. On the other hand, with the increasing use of CTA to investigate stroke etiology, symptomatic nonstenotic carotid lesions are now recognized more frequently, and the risk of recurrent events might indeed be high. However, given the small sample size, selection bias and biases in reporting results cannot be ruled out.

Eight of the 14 studies with SyNC reported stroke etiology, and in all of these, ESUS was the predominant etiology. As of today, data supporting nonstenotic carotid lesions as a possible etiology of stroke are not robust, and most of these patients are currently classified as having ESUS if other sources of stroke are ruled out.<sup>9,28</sup> The incidence of recurrent strokes was 2.6/100 person-years in patients with nonstenotic carotid lesions and otherwise unknown etiology, which may suggest that SyNC is potentially the etiology of these cryptogenic strokes.

Apart from the measurement of the degree of stenosis, growing literature uses high-definition vessel wall imaging of high-risk plaque features to identify patients at increased risk of recurrent stroke, despite low-grade stenosis.<sup>11,36</sup> In this meta-analysis, studies in both populations (especially SyNC) reported specific plaque features that predict a high recurrence rate, the most common being intraplaque hemorrhage. We found that the incidence rate of recurrent strokes is the same as that in symptomatic severe carotid stenosis, which should raise awareness of this high-risk subgroup. However, these studies are relatively small (total  $n = 31$ ) and few in

number ( $n = 3$ ). Also, our search strategy did not include specific terms like “intraplaque hemorrhage” and so forth because this was not our primary outcome, which may have led to under-reporting of these specific features. Even though the representation of the subgroup of patients with SyNC and high-risk plaque features in the currently existing literature is limited, these findings are thought-provoking and support the need for larger studies and further validation.

Another important aspect is the treatment of patients with symptomatic nonstenotic carotid plaques. Current guidelines rely on the measurement of the degree of stenosis to recommend carotid revascularization.<sup>3</sup> However, there is increasing evidence to suggest that unstable, inflamed, carotid plaques could rupture, causing stroke irrespective of the degree of stenosis.<sup>37</sup> Furthermore, studies have also demonstrated that certain subgroups of patients with nonstenotic carotid stenosis tend to have recurrent strokes despite the best medical management.<sup>28,37,38</sup> These observations suggest a limited efficacy of medical therapy in a subgroup of patients with SyNC with high-risk plaque features. Recent studies using high-resolution imaging to detect high-risk patients with SyNC have shown a benefit of carotid revascularization with almost no recurrence on follow-up.<sup>8,13</sup> These studies indicate that the degree of stenosis alone may not be sufficient to determine treatment strategies, and plaque features and vulnerability may become important considerations in the treatment decision-making.

#### Limitations

This meta-analysis has several limitations: First, many of the included studies for assessing the risk of first-ever stroke/TIA in nonstenotic carotid plaques were relatively old: Ten



of 25 were published before 2000, and the oldest study was published in 1984. Also, many of these studies traditionally classified the degree of stenosis as <30%, 30%–70%, and >70% before the NASCET definition. Because this classification system incorporates 50%–70% stenosis along with nonstenotic plaques, we excluded them to avoid the overestimation of results. Furthermore, there is heterogeneity both in the imaging technique and the underlying classification system used for characterizing carotid stenosis in the included studies. We addressed this issue using sensitivity analyses, stratifying by imaging technique. Last, only a few publications reported stroke etiology, and overall, the number of patients with ESUS and nonstenotic carotid plaques was provided infrequently. Even though our results are overall comparable with numbers reported in prior studies<sup>7</sup> of patients with ESUS and nonstenotic carotid plaques, overestimation of recurrent events might have occurred because other etiologies of stroke (eg, cardioembolic) could not be excluded.

## CONCLUSIONS

The risk of first-ever stroke/TIA with ASyNC in our meta-analysis was low, but once the patient was symptomatic, the risk of recurrent stroke/TIA in SyNC increased substantially, particularly when high-risk features such as intraplaque hemorrhage were present. Given the emerging evidence for an association between nonstenotic carotid plaques and stroke, one must consider it an etiology and investigate further to assess high-risk features. Presently, there is insufficient evidence to support a treatment strategy for this high-risk subgroup of patients with SyNC. Further research is needed to better investigate the natural history, progression from <50% to >50% stenosis, and potential treatment options such as more aggressive medical management or carotid revascularization of patients with nonstenotic carotid plaques.

Disclosures: Mayank Goyal—UNRELATED: Consultancy: Medtronic, Stryker, Mentice, MicroVention; Grants/Grants Pending: Medtronic, Stryker, Cerenovus\*; Patents (Planned, Pending or Issued): GE Healthcare, Comments: systems of acute stroke diagnosis; Royalties: GE Healthcare. \*Money paid to the institution.

## REFERENCES

- Mortimer R, Nachiappan S, Howlett DC. Carotid artery stenosis screening: where are we now? *Br J Radiology* 2018;91:20170380 [CrossRef Medline](#)
- Cheng SF, Brown MM, Simister RJ, et al. Contemporary prevalence of carotid stenosis in patients presenting with ischaemic stroke. *Br J Surg* 2019;106:872–78 [CrossRef Medline](#)
- Brott TG, Halperin JL, Abbara S, et al. ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Developed in collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography. *Catheter Cardiovasc Interv* 2013;81:E76–123 [CrossRef Medline](#)
- Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet* 1998;351:1379–87 [Medline](#)
- Ferguson GG, Eliasziw M, Barr HW, et al. The North American Symptomatic Carotid Endarterectomy Trial. *Stroke* 1999;30:1751–58 [CrossRef Medline](#)
- Coutinho JM, Derkatch S, Potvin ARJ, et al. Nonstenotic carotid plaque on CT angiography in patients with cryptogenic stroke. *Neurology* 2016;87:665–72 [CrossRef Medline](#)
- Ntaios G, Swaminathan B, Berkowitz SD, et al; NAVIGATE ESUS Investigators. Efficacy and safety of rivaroxaban versus aspirin in embolic stroke of undetermined source and carotid atherosclerosis. *Stroke* 2019;50:2477–85 [CrossRef Medline](#)
- Yoshida K, Fukumitsu R, Kurosaki Y, et al. Carotid endarterectomy for medical therapy-resistant symptomatic low-grade stenosis. *World Neurosurg* 2019;123:e543–48 [CrossRef Medline](#)
- Singh TD, Kramer CL, Mandrekar J, et al. Asymptomatic carotid stenosis: risk of progression and development of symptoms. *Cerebrovasc Dis* 2015;40:236–43 [CrossRef Medline](#)
- Bock RW, Gray-Weale AC, Mock PA, et al. The natural history of asymptomatic carotid artery disease. *J Vasc Surg* 1993;17:160–71 [CrossRef](#)
- Hosseini AA, Simpson RJ, Altaf N, et al. Magnetic resonance imaging plaque hemorrhage for risk stratification in carotid artery disease with moderate risk under current medical therapy. *Stroke* 2017;48:678–85 [CrossRef Medline](#)
- Kamtchum-Tatuene J, Wilman A, Saqqur M, et al. Carotid plaque with high-risk features in embolic stroke of undetermined source: systematic review and meta-analysis. *Stroke* 2020;51:311–14 [CrossRef Medline](#)
- Kashiwazaki D, Shiraishi K, Yamamoto S, et al. Efficacy of carotid endarterectomy for mild (<50%) symptomatic carotid stenosis with unstable plaque. *World Neurosurg* 2019;121:e60–69 [CrossRef Medline](#)
- Takai H, Uemura J, Yagita Y, et al. Plaque characteristics of patients with symptomatic mild carotid artery stenosis. *J Stroke Cerebrovasc Dis* 2018;27:1930–36 [CrossRef Medline](#)
- Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev* 2019;10:ED000142 [CrossRef Medline](#)
- Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097 [CrossRef Medline](#)
- AbuRahma AF, Cook CC, Metz MJ, et al. Natural history of carotid artery stenosis contralateral to endarterectomy: results from two randomized prospective trials. *J Vasc Surg* 2003;38:1154–61 [CrossRef Medline](#)
- Goessens BM, Visseren FL, Kappelle LJ, et al. Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. *Stroke* 2007;38:1470–75 [CrossRef Medline](#)
- Yamada K, Yoshimura S, Shirakawa M, et al. Asymptomatic moderate carotid artery stenosis with intraplaque hemorrhage: progression of degree of stenosis and new ischemic stroke. *J Clin Neurosci* 2019;63:95–99 [CrossRef Medline](#)
- de Haro J, Rodriguez-Padilla J, Bleda S, et al. Carotid stenting with proximal cerebral protection in symptomatic low-grade vulnerable recurrent carotid stenosis. *Ther Adv Chronic Dis* 2018;9:125–33 [CrossRef Medline](#)
- Freilinger TM, Schindler A, Schmidt C, et al. Prevalence of nonstenosing, complicated atherosclerotic plaques in cryptogenic stroke. *JACC Cardiovasc Imaging* 2012;5:397–405 [CrossRef Medline](#)

22. Gupta A, Mushlin AI, Kamel H, et al. **Cost-effectiveness of carotid plaque MR imaging as a stroke risk stratification tool in asymptomatic carotid artery stenosis.** *Radiology* 2015;277:927 [CrossRef Medline](#)
23. Hyafil F, Schindler A, Sepp D, et al. **High-risk plaque features can be detected in non-stenotic carotid plaques of patients with ischaemic stroke classified as cryptogenic using combined 18F-FDG PET/MR imaging.** *Eur J Nucl Med Mol Imaging* 2016;43:270–79 [CrossRef](#)
24. Komatsu T, Iguchi Y, Arai A, et al. **Large but nonstenotic carotid artery plaque in patients with a history of embolic stroke of undetermined source.** *Stroke* 2018;49:3054–56 [CrossRef Medline](#)
25. Singh N, Moody AR, Panzov V, et al. **Carotid intraplaque hemorrhage in patients with embolic stroke of undetermined source.** *J Stroke Cerebrovasc Dis* 2018;27:1956–59 [CrossRef Medline](#)
26. Xu Y, Yuan C, Zhou Z, et al. **Co-existing intracranial and extracranial carotid artery atherosclerotic plaques and recurrent stroke risk: a three-dimensional multicontrast cardiovascular magnetic resonance study.** *J Cardiovasc Magn Reson* 2016;18:90 [CrossRef Medline](#)
27. Altaf N, Daniels L, Morgan PS, et al. **Detection of intraplaque hemorrhage by magnetic resonance imaging in symptomatic patients with mild to moderate carotid stenosis predicts recurrent neurological events.** *J Vasc Surg* 2008;47:337–42 [CrossRef Medline](#)
28. Yoshida K, Sadamasa N, Narumi O, et al. **Symptomatic low-grade carotid stenosis with intraplaque hemorrhage and expansive arterial remodeling is associated with a high relapse rate refractory to medical treatment.** *Neurosurgery* 2012;70:1143–51 [CrossRef Medline](#)
29. Lee SK, Yun CH, Oh JB, et al. **Intracranial ictal onset zone in nonlesional lateral temporal lobe epilepsy on scalp ictal EEG.** *Neurology* 2003;61:757–64 [CrossRef Medline](#)
30. Ballotta E, Da Giau G, Meneghetti G, et al. **Progression of atherosclerosis in asymptomatic carotid arteries after contralateral endarterectomy: a 10-year prospective study.** *J Vasc Surg* 2007;45:516–22 [CrossRef Medline](#)
31. Wintermark M, Arora S, Tong E, et al. **Carotid plaque computed tomography imaging in stroke and nonstroke patients.** *Ann Neurol* 2008;64:149–57 [CrossRef Medline](#)
32. Adams HP, Bendixen BH, Kappelle LJ, et al. **Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST—Trial of Org 10172 in Acute Stroke Treatment.** *Stroke* 1993;24:35–41 [CrossRef Medline](#)
33. Petty GW, Brown RD, Whisnant JP, et al. **Ischemic stroke subtypes.** *Stroke* 2000;31:1062–68 [CrossRef](#)
34. [No authors listed] **Endarterectomy for asymptomatic carotid artery stenosis: Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.** *JAMA* 1995;273:1421–28 [Medline](#)
35. Halliday A, Mansfield A, Marro J, et al; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. **Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial.** *Lancet* 2004;363:1491–1502 [CrossRef Medline](#)
36. Gupta A, Baradaran H, Schweitzer AD, et al. **Carotid plaque MRI and stroke risk.** *Stroke* 2013;44:3071–77 [CrossRef Medline](#)
37. Truijman MT, Kooi ME, van Dijk AC, et al. **Plaque at RISK (PARISK): prospective multicenter study to improve diagnosis of high-risk carotid plaques.** *Int J Stroke* 2014;9:747–54 [CrossRef Medline](#)
38. Karlsson L, Kängfjård E, Hermansson S, et al. **Risk of recurrent stroke in patients with symptomatic mild (20–49% NASCET) carotid artery stenosis.** *Eur J Vasc Endovasc Surg* 2016;52:287–94 [CrossRef Medline](#)
39. Alexandrova NA, Gibson WC, Norris JW, et al. **Carotid artery stenosis in peripheral vascular disease.** *J Vasc Surg* 1996;23:645–49 [CrossRef Medline](#)
40. Chen Q, Liu Y, Pei L, et al. **Characteristics of carotid artery disease (CAD) and presenting cerebrovascular symptoms in an aged group.** *Int J Cardiovasc Imaging* 2009;25:127–32 [CrossRef Medline](#)
41. Högberg D, Björck M, Mani K, et al. **Five year outcomes in men screened for carotid artery stenosis at 65 years of age: a population based cohort study.** *Eur J Vasc Endovasc Surg* 2019;57:759–66 [CrossRef Medline](#)
42. Johnson BF, Verlato F, Bergelin RO, et al. **Clinical outcome in patients with mild and moderate carotid artery stenosis.** *J Vasc Surg* 1995;21:120–26 [CrossRef Medline](#)
43. Jungquist G, Nilsson B, Ostberg H, et al. **Carotid artery blood flow velocity related to transient ischemic attack and stroke in a population study of 69-year-old men.** *Stroke* 1989;20:1327–30 [CrossRef Medline](#)
44. Kaul S, Alladi S, Mridula KR, et al. **Prevalence and risk factors of asymptomatic carotid artery stenosis in Indian population: an 8-year follow-up study.** *Neurol India* 2017;65:279–85 [CrossRef Medline](#)
45. Lewis RF, Abrahamowicz M, Côté R, et al. **Predictive power of duplex ultrasonography in asymptomatic carotid disease.** *Ann Intern Med* 1997;127:13–20 [CrossRef Medline](#)
46. Mackey AE, Abrahamowicz M, Langlois Y, et al. **Outcome of asymptomatic patients with carotid disease: Asymptomatic Cervical Bruit Study Group.** *Neurology* 1997;48:896–903 [CrossRef Medline](#)
47. Masoomi R, Shah Z, Dawn B, et al. **Progression of external and internal carotid artery stenosis is associated with a higher risk of ischemic neurologic events in patients with asymptomatic carotid artery stenosis.** *Vasc Med* 2017;22:418–23 [CrossRef Medline](#)
48. Moore WS, Boren C, Malone JM, et al. **Natural history of nonstenotic, asymptomatic ulcerative lesions of the carotid artery.** *Arch Surg* 1978;113:1352–59 [CrossRef Medline](#)
49. Noh M, Kwon H, Jung CH, et al. **Impact of diabetes duration and degree of carotid artery stenosis on major adverse cardiovascular events: a single-center, retrospective, observational cohort study.** *Cardiovasc Diabetol* 2017;16:74:06 [CrossRef Medline](#)
50. Polak JF, Shemanski L, O'Leary DH, et al. **Hypochoic plaque at US of the carotid artery: an independent risk factor for incident stroke in adults aged 65 years or older: Cardiovascular Health Study.** *Radiology* 1998;208:649–54 [CrossRef Medline](#)
51. Prabhakaran S, Rundek T, Ramas R, et al. **Carotid plaque surface irregularity predicts ischemic stroke: the northern Manhattan study.** *Stroke* 2006;37:2696–701 [CrossRef Medline](#)
52. Roederer GO, Langlois YE, Jager KA, et al. **The natural history of carotid arterial disease in asymptomatic patients with cervical bruits.** *Stroke* 1984;15:605–13 [CrossRef Medline](#)
53. Tong Y, Royle J. **Outcome of patients with symptomless carotid bruits: a prospective study.** *Cardiovasc Surg* 1996;4:174–80 [CrossRef Medline](#)
54. Yamada N, Higashi M, Otsubo R, et al. **Association between signal hyperintensity on T1-weighted MR imaging of carotid plaques and ipsilateral ischemic events.** *AJNR Am J Neuroradiol* 2007;28:287–92 [Medline](#)
55. Underhill HR, Yuan C, Yarnykh VL, et al. **Arterial remodeling in [corrected] subclinical carotid artery disease.** *JACC Cardiovasc Imaging* 2009;2:1381–89 [CrossRef Medline](#)
56. Zhang Y, Fang X, Hua Y, et al. **Carotid artery plaques, carotid intima-media thickness, and risk of cardiovascular events and all-cause death in older adults: a 5-year prospective, community-based study.** *Angiology* 2018;69:120–29 [CrossRef Medline](#)
57. Zierler RE, Kohler TR, Strandness DE. **Duplex scanning of normal or minimally diseased carotid arteries: correlation with arteriography and clinical outcome.** *J Vasc Surg* 1990;12:447–55 [CrossRef Medline](#)
58. Ishikawa M, Sugawara H, Tsuji T, et al. **Clinical significance of the coexistence of carotid artery plaque and white matter disease in patients with symptomatic cerebral infarction.** *Clin Neurol Neurosurg* 2017;163:179–85 [CrossRef Medline](#)